Lorenzo's Oil
Phase 3Small molecule
Lorenzo's Oil is one of 13 small molecule programs targeting Adrenomyeloneuropathy. It is currently in Phase 3.
2
Indications
2
Total Trials
0
Active Trials
12
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
11 competitors in Adrenoleukodystrophy
#DrugCompanyPhaseTrials
1Mirapex
Boehringer IngelheimApproved
Busulfex
Akero TherapeuticsApproved
Cytoxan
BBaxter Healthcare Corporation
Approved
Lorenzo's Oil
UUniversity of Minnesota
Phase 3
Thalomid
Bristol-Myers SquibbPreclinical
Mesenchymal Stem Cells
JJiangsu Topcel-KH Pharmaceutical Co., Ltd.
Phase 1
Sobetirome
NNeuroVia, Inc.
Phase 2
Interferon-Beta
BiogenPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Adrenomyeloneuropathy1 trial
A Phase III Trial of Lorenzo's Oil in Adrenomyeloneuropathy
Terminated·EEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)·Phase 3·NCT00545597·240 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Lorenzo's Oil. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- UUniversity of Minnesota